Six-month open-label study showed clinically meaningful improvements in kidney function and disease in patients with Type 2 diabetic nephropathy. 71% achieved a >30% reduction in UP/Cr, a key indicator of kidney damage. 71% demonstrated improved or stabilized eGFR, signaling preserved...
Read More Details
Finally We wish PressBee provided you with enough information of ( Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting )
Also on site :
- Rock Legend Shares Bold Message About L.A. Protests
- Tony Awards draw best audience in 6 years for CBS
- Ax-wielding man at Pacific Beach library faces preliminary hearing